[DS8201-A-U207] A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-overexpressing locally advanced, unresectable or metastatic colorectal cancer (Destiny-CRC02)
Administered By
Awarded By
Contributors
- Strickler, John Principal Investigator
Start/End
- April 22, 2021 - May 9, 2026